Source-grounded facts extracted from LifeMD, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
LifeMD, Inc. reported the first quarter ended March 31, 2026 results: revenue $50.2 million. Guidance reaffirmed.
“2026. A copy of the press release is furnished herewith as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- LifeMD Reports First Quarter 2026 Results ● First quarter 2026 revenue of $50.2 million and adjusted EBITDA loss of $4.5 million, above and in line, respectively, with the Company’s guidance. ● Gross margin increased approximately 420 basis points to 88%, versus”
LifeMD, Inc. entered into Credit Agreement with Citizens Bank, N.A. valued at $30 million (effective 2026-01-02).
“On January 2, 2026, LifeMD, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with Citizens Bank, N.A. (the “Lender”), which provides for a senior secured revolving credit facility in an aggregate outstanding amount not exceeding $30 million (the “Credit Facility”)”
LifeMD, Inc. incurred revolving credit of $30 million with Citizens Bank, N.A. at Term SOFR plus 1.50% to 2.25% or Alternate Base Rate plus 0.50% to 1.25% maturing January 2, 2029.
“On January 2, 2026, LifeMD, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with Citizens Bank, N.A. (the “Lender”), which provides for a senior secured revolving credit facility in an aggregate outstanding amount not exceeding $30 million (the “Credit Facility”) to support potential corporate development and/or shareholder value creation initiatives. The Credit Facility may be increased in the aggregate principal amount of up to $20 million on the terms and subject to the conditions described in the Credit Agreement. In connection with the Credit Agreement, among other things, the Company issued a revolving loan note to the Lender for any loans that may be made under the Credit Facility. Additionally, among other things, the Company and its subsidiaries entered into a pledge and security agreement and a guarantee agreement to provide credit support for the Credit Facility. The Credit Facility matures on January 2, 2029. The terms of the Credit Facility pr”
LifeMD, Inc. completed a disposition involving Lion Buyer, LLC for up to $52.0 million (closed 2025-11-04).
“aggregate purchase price paid at close and 53.8% ($28.0 million) subject to future performance targets, for an aggregate purchase consideration paid to the Sellers of up to $52.0 million: ● 46.2% of the aggregate purchase price consists of a cash payment equal to the base purchase price of $24.0 million, subject to adjustments for net working capital, cash,”
LifeMD, Inc. engaged PricewaterhouseCoopers LLP as its auditor.
“On August 18, 2025, the Company, with the approval of the Audit Committee of the Company’s Board of Directors, appointed PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm for the year ending December 31, 2025.”
LifeMD, Inc. dismissed CBIZ CPAs P.C. as its auditor.
“Dismissal of Independent Registered Public Accounting Firm On August 15, 2025, LifeMD, Inc. (the “Company”), with the approval of the Audit Committee of the Company’s Board of Directors, dismissed CBIZ CPAs P.C. (“CBIZ CPAs”) as the Company’s independent registered public accounting firm.”
Naveen Bhatia resigned as Member of the Board of Directors at LifeMD, Inc..
“Effective October 25, 2024, Naveen Bhatia voluntarily resigned from his position as a member of the board of directors (the “Board”) of LifeMD, Inc. (the “Company”).”
Calum MacRae was appointed as Member of the Board of Directors at LifeMD, Inc..
“On April 26, 2024, Calum MacRae was appointed to the Board of Directors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.